First-In-Class Drug Discovery Role Split

First-in-class drug discovery role split is the episode’s interpretation of research showing that small BioTech companies and academic institutions originate many oncology First-in-Class molecules, while large pharma often owns, co-owns, launches, or commercializes them by approval. 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 treats this as a workflow division rather than a simple ranking of who is more innovative.

The source adds two cautions. Company type can change between discovery and launch, and the visible successful BioTech cases may hide many failed small-company experiments. Large pharma can look less novel because it filters more heavily before expensive clinical work, but that filtering may improve success rates and commercial outcomes.

Key Claims

• Small BioTech teams may be more active in early discovery and willingness to push novel ideas.
• Large pharma often enters later through acquisition, licensing, partnership, or co-development.
• “Who discovered it” and “who captured value” are different questions.
• Survivorship bias can exaggerate the apparent superiority of small-company innovation.
• Big-company clinical, regulatory, and commercial machinery helps explain why large pharma-discovered or large pharma-held assets can become larger blockbusters.

Connections

• Academic Biotech Translation - academic origin side of the split.
• Clinical Development Capability - value-capture layer after discovery.
• Global Pharma Commercialization - launch and sales layer.
• Biotech Capital Cycle - funding and exit system that lets assets move from small teams to large companies.